Art. -Nr.: HY-123071A

Box5 TFA

13 Cited Publications

Kundenbewertung

Based on 13 publication(s) in Google Scholar

Box5 TFA is a potent Wnt5a antagonist. Box5 TFA inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca²⁺ release. Box5 TFA inhibits cell migration. Box5 TFA has the potential for the research of melanoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.50%
Formel: C₃₀H₅₀N₆O₁₃S₂·xC₂HF₃O₂
Molecular Weight:766.88 (free base)

Speicherung:

Sealed storage, away from moisture and light, under nitrogen.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Box5 TFA Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (13)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Wnt5A

Alle Wnt Isoform-spezifische Produkte anzeigen :

In Vitro

Box5 TFA (100 μM) decreases the expression of rWnt5a (0.1 μg/mL) stimulated p-MARCKS in A2058 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

Appearance Solid
Molecular Weight 766.88 (free base)
Formel C₃₀H₅₀N₆O₁₃S₂·xC₂HF₃O₂
Color White to off-white
Sequence

t-Boc-Met-Asp-Gly-Cys-Glu-Leu
Sequence Shortening

t-Boc-MDGCEL
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture and light, under nitrogen

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Publications (13)

All WBCell Proliferation/Viability AssayCell Imaging/StainingHistological Imaging/Staining

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Single-Cell RNA Sequencing Identifies MMP11+ Cancer-Associated Fibroblasts as Drivers of Angiogenesis and Bladder Cancer Progression. [Abstract]

2025 Jun 24:e02774. PMID: 40552583
J Hazard Mater

PFPeA exposure drives hepatoxicity and liver fibrosis via oxidative stress/Wnt5a-induced hepatocyte senescence. [Abstract]

2026 Feb 1:503:141085. PMID: 41529635

Box5 TFA purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2026 Feb 1:503:141085. [Abstract]

Protein level of p21, p16 and IL-6 after inhibiting Wnt5a with Box5 (100 μM; 24 h) in THLE-2 cells, and statistical analysis, α-Tubulin were used as control. The results showed that Box5 decreased the senescence related proteins.

Box5 TFA purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2026 Feb 1:503:141085. [Abstract]

Representative images of SA-β-Gal staining after inhibiting Wnt5a with Box5 (100 μM; 24 h) in THLE-2 cells. SA-β-Galactosidase staining confirmed that inhibition of Wnt5a decreased the senescence level of hepatocytes induced by PFPeA.
Nano Today

2024 Apr, 55, 102201.
J Immunother Cancer

Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts. [Abstract]

2025 Mar 22;13(3):e010555. PMID: 40121032
J Neuroinflammation

Wnt5a/β-catenin-mediated epithelial-mesenchymal transition: a key driver of subretinal fibrosis in neovascular age-related macular degeneration. [Abstract]

2024 Mar 26;21(1):75. PMID: 38532410

Box5 TFA purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2024 Mar 26;21(1):75. [Abstract]

The cell viability of ARPE-19 cells examined with CCK-8 assay after treatment with the indicated doses of Box5 for 48 hours. The Vehicle Control groups for Box5 contained DMSO concentrations of 0.2% and 2%, respectively.

Box5 TFA purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2024 Mar 26;21(1):75. [Abstract]

The protein levels of fibronectin, Wnt5a, Dvl2, and Naked1 in TGFβ1 (10 ng/mL)-treated ARPE-19 cells with or without different concentrations of Box5 (10, 45 and 90 μmol/L) for 48 h. Box5 suppressed the TGFβ1-mediated up-regulation of fibronectin, Wnt5a, Dvl2, and Naked1 in a dose-dependent manner.

Box5 TFA purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2024 Mar 26;21(1):75. [Abstract]

The effects of intravitreal injections of FH535 or Box5 (90 μmol/L) on β-catenin and α-SMA expression within the CNV lesions in mice at day 21 after laser induction, along with the corresponding quantitative analysis. Box5 (90 μmol/L) treatment significantly reduced the immunostaining areas of active β-catenin by 47.39% (p = 0.00002, n = 10).
J Transl Med

Single-cell and spatial transcriptome profiling reveal CTHRC1+ fibroblasts promote EMT through WNT5A signaling in colorectal cancer. [Abstract]

2025 Mar 6;23(1):282. PMID: 40050872
J Mol Cell Biol

Canonical Wnt signaling affects calcium homeostasis in serum-treated AC16 cells through MLN-mediated SERCA2a regulation. [Abstract]

2025 Dec 5:mjaf050. PMID: 41348974
J Mol Cell Biol

Wnt/β-catenin pathway induces cardiac dysfunction via AKAP6-mediated RyR2 phosphorylation and sarcoplasmic reticulum calcium leakage. [Abstract]

2025 Jul 28;17(2):mjaf002. PMID: 40097291
J Ethnopharmacol

Dendrobine ameliorates non-alcoholic fatty liver disease by inhibiting mitochondrial fission through modulation of the Wnt5a/p-CaMKII/p-Drp1 signaling axis. [Abstract]

2026 May 23:363:121445. PMID: 41763618
J Cell Mol Med

Decoding the Oncogenic Role of GNG10 in Colorectal Cancer: A Non-Canonical Wnt Pathway-Driven Mechanism. [Abstract]

2026 Jun;30(11):e71170. PMID: 42252561
Sci Rep

DOCK1 inhibitor Box5 (TFA) suppresses proliferation of AML cell lines and prolongs survival in AML xenograft models. [Abstract]

2026 May 11;16(1):21377. PMID: 42108312
Oral Dis

Synovial osteoclastogenesis mediated by chondrocyte-secreted TNFα promotes TMJ condylar resorption. [Abstract]

2024 May 8. PMID: 38720613
Odontology

Fusobacterium nucleatum promotes senescence of human oral mucosa fibroblasts via the Wnt5A/mTOR pathway. [Abstract]

2026 Jan 21. PMID: 41559469

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jenei V, et al. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19473-8. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Box5 TFA

13 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Box5 TFA

Peptide Library

Publications Citing Use of MedChemExpress (MCE) Box5 TFA

Alle Wnt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Box5 TFA

Peptide Library

Publications Citing Use of MedChemExpress (MCE) Box5 TFA

Alle Wnt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Box5 TFA Related Classifications

HY-123071A Related Classifications